Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering reported Q1 2026 financial results with a net loss of $13.5 million ($0.21 per share), an improvement from the $15.0 million loss in Q1 2025. The company ended the quarter with $198.6 million in cash and marketable securities, maintaining a runway into 2029. Clinically, Immuneering highlighted an upcoming oral presentation at the ASCO Annual Meeting on June 1, featuring new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib plus mGnP in its Phase 2a trial. The pivotal Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer is now recruiting, with first patient dosing on track for mid-2026.
Key figures
- Revenue
- 0
- Drug Name
- atebimetinib
- Guidance
- Cash runway sufficient to fund operations into 2029
- Phase Of Trial
- Phase 2a
- Ga expenses
- 4682495
- Rd expenses
- 10645222
- Cash and securities
- 198600000
- Weighted avg shares
- 64658809
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.